Alpha Mannosidosis Market size was valued at USD 9.92 billion in 2021, growing at a significant CAGR of 17.8% from 2022–2028. The market is anticipated to expand during the forecast period due to rising research expenditures. Only one firm currently offers treatments for the rare hereditary illness alpha mannosidosis. However, several businesses are developing items that will drive up demand in the market throughout the projection period. For example, the EU clinical trials database includes 39,219 clinical trials with a EudraCT protocol in 2020, 6,426 of which involve participants under 18. Therefore, the alpha mannosidosis market is expanding due to rising research expenditures.